Skip to main content
. 2021 Dec 7;11:740427. doi: 10.3389/fonc.2021.740427

Figure 4.

Figure 4

Landscape of genomic alterations in pre-NAC tumors and post-NAC residual non-cancerous tissues (pCR) or cancerous tissues (non-pCR). (A) In pre-NAC tumors, the top 15 mutated genes were TP53, PIK3CA, MLL3, ZFHX3, CDK12, EP300, ERBB2, GRIN2A, KDR, MLL2, NCOR1, NF1, NOTCH4, ARID1A, and ARID1B. (B) In post-NAC residual non-cancerous tissues (pCR) or cancerous tissues (non-pCR), the top 15 mutated genes were TP53, PIK3CA, ARID1A, CDH23, LRP1B, NSD1, ALK, ATRX, AXL, BLM, BRCA1, BRCA2, BRD2, CBFB, and EPHB6. cliniORR, clinical objective response rate; menopause, menopause; ER, estrogen receptor; PR, progesterone receptor; HER-2_, human epidermal growth factor receptor 2. Missense_mutation, nonsense mutation; frame_shift_ins, frame shift insertion mutation; spice_site, splicing mutation; frame_shift del, Frameshift deletion mutation, nonsense mutation, nonsense mutation, in frame del, frameshift deletion mutation, multi hit, multiple site mutation of a same gene; ClinORR 0: Complete Response (CR), 1: Partial Response (PR), 2: Stable Disease (SD), 3: Progressive Disease (PD); ER, PR, HER_2, 0: Negative, 1: +, 2: ++, 3: +++.